Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
Genenta Science (Nasdaq: GNTA) and ANEMOCYTE announced an expanded strategic collaboration on an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform, dated October 24, 2025. The agreement builds on an existing partnership and makes Genenta's clinically validated LVV Plasmid DNA platform, originating from research by Professor Luigi Naldini, available to ANEMOCYTE and its clients.
The collaboration aims to supply top-quality plasmid DNA across R&D to GMP grade and from preclinical to commercial stages, supporting scalable advanced therapy program development and broadening ANEMOCYTE's offering to customers.
Genenta Science (Nasdaq: GNTA) e ANEMOCYTE hanno annunciato un ampliamento della collaborazione strategica su una piattaforma tecnologica di DNA plasmidico LVV (vector lentiviral) pronta all’uso, datata 24 ottobre 2025. L’accordo si inserisce in una partnership esistente e mette a disposizione di ANEMOCYTE e dei suoi clienti la piattaforma LVV Plasmid DNA clinicamente validata di Genenta, originaria della ricerca del professor Luigi Naldini.
La collaborazione ha l’obiettivo di fornire DNA plasmidico di alta qualità, dalla R&D al livello GMP e dalle fasi precliniche a quelle commerciali, sostenendo lo sviluppo di programmi di terapie avanzate scalabili e ampliando l’offerta di ANEMOCYTE ai suoi clienti.
Genenta Science (Nasdaq: GNTA) y ANEMOCYTE anunciaron una ampliación de la colaboración estratégica en una plataforma de tecnología de ADN plasmídico de vectores lentivirales (LVV) lista para usar, fechada el 24 de octubre de 2025. El acuerdo se apoya en una asociación existente y pone a disposición de ANEMOCYTE y sus clientes la plataforma de ADN plasmídico LVV clínicamente validada de Genenta, originaria de la investigación del profesor Luigi Naldini.
La colaboración tiene como objetivo suministrar ADN plasmídico de alta calidad desde I+D hasta grado GMP y desde etapas preclínicas hasta comerciales, apoyando el desarrollo de programas de terapias avanzadas escalables y ampliando la oferta de ANEMOCYTE a sus clientes.
Genenta Science (나스닥: GNTA)와 ANEMOCYTE가 즉시 사용 가능한 렌티바이러스 벡터 LVV 플라스미드 DNA 기술 플랫폼에 대한 확장된 전략적 협력을 발표했습니다. 날짜는 2025년 10월 24일입니다. 이 계약은 기존 파트너십을 바탕으로 하며 Genenta의 임상적으로 검증된 LVV 플라스미드 DNA 플랫폼을 ANEMOCYTE 및 그 고객들에게 제공합니다. 이 플랫폼은 루이지 나르디니 교수의 연구에서 기인했습니다.
협력의 목표는 연구개발(R&D)에서 GMP 등급까지, 전임상에서 상업 단계에 이르기까지 고품질의 플라스미드 DNA를 공급하고, 확장 가능한 첨단 치료제 프로그램 개발을 지원하며 ANEMOCYTE의 고객 제공을 확대하는 것입니다.
Genenta Science (Nasdaq: GNTA) et ANEMOCYTE ont annoncé une extension de leur collaboration stratégique sur une plateforme technologique de DNA plasmidique LVV prête à l’emploi, datée du 24 octobre 2025. L’accord s’appuie sur un partenariat existant et met à disposition d’ANEMOCYTE et de ses clients la plateforme LVV Plasmid DNA cliniquement validée de Genenta, issue de la recherche du professeur Luigi Naldini.
La collaboration vise à fournir un DNA plasmidique de haute qualité, du stade R&D jusqu’au niveau GMP, et des phases précliniques jusqu’à la commercialisation, soutenant le développement de programmes de thérapies avancées évolutifs et élargissant l’offre d’ANEMOCYTE à ses clients.
Genenta Science (Nasdaq: GNTA) und ANEMOCYTE kündigten eine erweiterte strategische Zusammenarbeit an eine sofort verfügbare Plattform für lentivirale Vektor-Plasmid-DNA (LVV-Plasmid-DNA) an, datiert auf den 24. Oktober 2025. Die Vereinbarung baut auf einer bestehenden Partnerschaft auf und macht Genentas klinisch validierte LVV-Plasmid-DNA-Plattform, die aus der Forschung von Professor Luigi Naldini hervorgegangen ist, ANEMOCYTE und dessen Kunden zugänglich.
Ziel der Zusammenarbeit ist es, hochwertiges Plasmid-DNA von F&E bis GMP-Grad und von der Präklinik bis zur Kommerzialisierung bereitzustellen, die Entwicklung skalierbarer Therapienprogramme zu unterstützen und ANEMOCYTES Angebot für Kunden zu erweitern.
Genenta Science (ناسداك: GNTA) وANEMOCYTE أ علنا عن توسيع التعاون الاستراتيجي بشأن منصة تقنية DNA بلازميدية للطُعَيمات الحاملة للفيروسات القهرية LVV جاهزة للاستخدام، بتاريخ 24 أكتوبر 2025. يعتمد الاتفاق على شراكة قائمة ويتيح لـ ANEMOCYTE وعملائها الوصول إلى منصة LVV Plasmid DNA التي تم التحقق من صلاحيتها سريريًا من Genenta، والتي نشأت من أبحاث البروفيسور لوغي نالديني.
يهدف التعاون إلى توفير DNA بلازميدي عالي الجودة عبر المراحل من البحث والتطوير وحتى مستوى GMP ومن المراحل ما قبل السريرية إلى المراحل التجارية، دعم تطوير برامج العلاج المتقدم القابلة للتوسع وتوسيع عرض ANEMOCYTE للعملاء.
Genenta Science (纳斯达克：GNTA) 与 ANEMOCYTE 宣布在一个现成可用的慢病毒载体 LVV 质粒 DNA 技术平台上的扩展战略合作，日期为 2025 年 10 月 24 日。该协议建立在现有伙伴关系之上，使 Genenta 经临床验证的 LVV 质粒 DNA 平台（源自 Naldini 教授的研究）向 ANEMOCYTE 及其客户提供。
本次合作旨在从研发到 GMP 级别、从前临床到商业阶段，提供高质量的质粒 DNA，支持可扩展的先进治疗方案开发，并扩大 ANEMOCYTE 面向客户的服务范围。
- None.
- None.
Insights
Expanded LVV plasmid DNA partnership likely strengthens manufacturing reach but lacks direct financial details, so near-term impact is neutral.
By licensing access to its clinically validated LVV Plasmid DNA platform, Genenta enables ANEMOCYTE to offer a vertically consistent supply chain from R&D to GMP grade, which can shorten development timelines for clients and improve material reliability.
Benefits depend on commercial uptake, contract terms, and capacity scale; none of these financial or volume metrics are disclosed, so revenue or margin effects remain unquantified. Operational or regulatory hurdles in GMP manufacturing could affect timelines.
Watch for concrete customer contracts, disclosed capacity or pricing terms, and any
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing successful partnership between the two companies, which has focused on the production of Plasmid DNA.
The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This established and proven technology will enable ANEMOCYTE to enhance its offering to clients, providing a reliable source of top-quality materials from R&D to GMP grade, from preclinical to commercial stages.
"Our expanded collaboration with ANEMOCYTE represents a natural progression of a successful partnership in plasmid DNA manufacturing,” said Pierluigi Paracchi, CEO at Genenta Science. “By making our clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry.”
Marco Ferrari, CEO at ANEMOCYTE added, "Our collaboration with Genenta has already yielded excellent results. By formalizing this new partnership, we are ensuring our clients have access to a robust, well-established platform for their advanced therapy programs, backed by Genenta's extensive track record."
This collaboration marks a significant milestone for both companies and underscores their shared commitment to supporting the life science industry with innovative and reliable solutions.
About Anemocyte: Anemocyte is a Biotech Manufacturing Organization (“BMO”) based in Italy, offering comprehensive development and manufacturing services and providing innovative solutions and products from R&D to GMP. Specialized in the research, development, and production of pDNA and mRNA, Anemocyte brings over 25 years of expertise in innovative therapies and related starting materials.
About Genenta Science: Genenta Science (Nasdaq: GNTA) is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for the treatment of a variety of solid tumor cancers. Genenta’s first-in-class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow-derived myeloid cells and enables a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (“GBM”) patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and the inhibition of myeloid-induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta’s treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
Forward-Looking Statements
Statements in this press release may contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding to be provided by the Mandatory Convertible Bond, the completion and timing of Genenta’s phase 2A clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its phase 1 clinical trial for metastatic RCC or any related studies, as well as Genenta’s ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied.Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.
Genenta Science Media
Tiziana Pollio, Mobile: +39 348 23 15 143
Email: tiziana.pollio@genenta.com
Anemocyte Media
Telephone +39 0299372311
Email: media@anemocyte.com
www.anemocyte.com
FAQ
What did Genenta (GNTA) and ANEMOCYTE announce on October 24, 2025?
How will the Genenta and ANEMOCYTE partnership affect plasmid DNA supply for advanced therapies?
Does the October 24, 2025 announcement state any financial terms or revenue guidance for GNTA?
What technology from Genenta is being shared with ANEMOCYTE in the GNTA partnership?
Will the GNTA and ANEMOCYTE collaboration support commercial-stage manufacturing?
Who commented on the strategic partnership in the October 24, 2025 Genenta announcement?
